MX2022009677A - Composiciones para el tratamiento de enfermedades oculares. - Google Patents

Composiciones para el tratamiento de enfermedades oculares.

Info

Publication number
MX2022009677A
MX2022009677A MX2022009677A MX2022009677A MX2022009677A MX 2022009677 A MX2022009677 A MX 2022009677A MX 2022009677 A MX2022009677 A MX 2022009677A MX 2022009677 A MX2022009677 A MX 2022009677A MX 2022009677 A MX2022009677 A MX 2022009677A
Authority
MX
Mexico
Prior art keywords
ocular diseases
edonentan
agent
compositions
treatment
Prior art date
Application number
MX2022009677A
Other languages
English (en)
Spanish (es)
Inventor
Zhongli Ding
Sevgi Gurkan
David Floyd
Original Assignee
Perfuse Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perfuse Therapeutics Inc filed Critical Perfuse Therapeutics Inc
Publication of MX2022009677A publication Critical patent/MX2022009677A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MX2022009677A 2020-02-06 2021-02-03 Composiciones para el tratamiento de enfermedades oculares. MX2022009677A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062971002P 2020-02-06 2020-02-06
US202063010212P 2020-04-15 2020-04-15
PCT/US2021/016414 WO2021158663A1 (en) 2020-02-06 2021-02-03 Compositions for treatment of ocular diseases

Publications (1)

Publication Number Publication Date
MX2022009677A true MX2022009677A (es) 2022-09-09

Family

ID=77200537

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009677A MX2022009677A (es) 2020-02-06 2021-02-03 Composiciones para el tratamiento de enfermedades oculares.

Country Status (11)

Country Link
US (2) US11873279B2 (cg-RX-API-DMAC10.html)
EP (1) EP4100406A4 (cg-RX-API-DMAC10.html)
JP (2) JP2023512763A (cg-RX-API-DMAC10.html)
KR (1) KR20220143685A (cg-RX-API-DMAC10.html)
CN (1) CN115103842A (cg-RX-API-DMAC10.html)
AU (1) AU2021217358A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022015579A2 (cg-RX-API-DMAC10.html)
CA (1) CA3168810A1 (cg-RX-API-DMAC10.html)
IL (1) IL294873A (cg-RX-API-DMAC10.html)
MX (1) MX2022009677A (cg-RX-API-DMAC10.html)
WO (1) WO2021158663A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7664239B2 (ja) * 2019-10-30 2025-04-17 パフューズ セラピューティクス, インコーポレイテッド エンドセリンレセプターアンタゴニストを使用する眼疾患の処置
CA3168810A1 (en) 2020-02-06 2021-08-12 Perfuse Therapeutics, Inc. Compositions for treatment of ocular diseases
BR112023022705A2 (pt) 2021-04-30 2024-01-16 Perfuse Therapeutics Inc Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares
CN117295520A (zh) * 2021-04-30 2023-12-26 珀弗斯治疗股份有限公司 使用内皮素受体拮抗剂治疗眼部疾病
WO2025137005A1 (en) * 2023-12-20 2025-06-26 Perfuse Therapeutics, Inc. Methods of preparing drug delivery systems for the treatment of ocular diseases
AU2024405327A1 (en) * 2023-12-20 2026-07-02 Perfuse Therapeutics, Inc. Methods of preparing drug delivery systems for the treatment of ocular diseases

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4282793A (en) 1992-04-10 1993-11-18 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A microneedle for injection of ocular blood vessels
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
CZ20032350A3 (en) 2001-02-02 2004-03-17 Merck Patent Gmbh PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS
US20030176356A1 (en) * 2001-04-24 2003-09-18 University Of North Texas Health Science Center Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
PL2424530T3 (pl) 2009-04-30 2016-07-29 Univ Midwestern Sposób i kompozycja do leczenia cukrzycowej kwasicy ketonowej
US20110082151A1 (en) 2009-06-12 2011-04-07 Auspex Pharmaceuticals, Inc. Sulfonylurea modulators of endothelin receptor
AR080888A1 (es) 2010-04-12 2012-05-16 R Tech Ueno Ltd Uso de un derivado de acido graso para producir una composicion oftalmica
ES2813383T3 (es) 2013-12-19 2021-03-23 Tassos Georgiou Composición de ácidos grasos omega 3 para tratar enfermedades que implican daños en el sistema nervioso
RU2016133980A (ru) * 2014-01-23 2018-03-01 Экебиа Терапьютикс, Инк. Композиции и способы для лечения заболеваний глаз
ES2584534B1 (es) 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
JP2018522942A (ja) 2015-05-29 2018-08-16 エッジ セラピューティクス インコーポレイテッド 視力障害を低減するための組成物及び方法
JP6745594B2 (ja) * 2015-11-26 2020-08-26 持田製薬株式会社 ピラゾール誘導体の塩の結晶
WO2017217967A1 (en) 2016-06-13 2017-12-21 Noveome Biotherapeutics, Inc. Novel methods for delivering therapeutic agents to the eye via nasal passages
WO2018185516A1 (en) * 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
US11286274B2 (en) 2017-06-19 2022-03-29 Mitopower Llc Nicotinamide riboside derivatives and their uses
US10905770B2 (en) 2017-07-17 2021-02-02 Macregen, Inc. Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases
KR102771305B1 (ko) * 2017-09-15 2025-02-24 모찌다 세이야쿠 가부시끼가이샤 테트라히드로나프틸우레아 유도체의 결정
WO2019210194A1 (en) 2018-04-26 2019-10-31 Vitrisa Therapeutics, Inc. Pegylated compositions for ocular use, and methods thereof
JP7664239B2 (ja) 2019-10-30 2025-04-17 パフューズ セラピューティクス, インコーポレイテッド エンドセリンレセプターアンタゴニストを使用する眼疾患の処置
CA3168810A1 (en) 2020-02-06 2021-08-12 Perfuse Therapeutics, Inc. Compositions for treatment of ocular diseases

Also Published As

Publication number Publication date
CA3168810A1 (en) 2021-08-12
AU2021217358A1 (en) 2022-09-08
US20230120974A1 (en) 2023-04-20
US11873279B2 (en) 2024-01-16
CN115103842A (zh) 2022-09-23
IL294873A (en) 2022-09-01
EP4100406A1 (en) 2022-12-14
KR20220143685A (ko) 2022-10-25
BR112022015579A2 (pt) 2022-10-11
JP2023512763A (ja) 2023-03-29
EP4100406A4 (en) 2023-07-05
JP2025120268A (ja) 2025-08-15
WO2021158663A1 (en) 2021-08-12
US20240109876A1 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
Kennedy et al. Selective laser trabeculoplasty: an update
NZ588938A (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
MX2022005063A (es) Tratamiento de enfermedades oculares con antagonistas de receptor de endotelina.
WO2019209955A3 (en) Use of pilocarpine hydrochloride for the treatment of ocular conditions
BR112022015579A2 (pt) Composições para tratamento de doenças oculares
TW200633709A (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
EP4302734A3 (en) Ocular delivery systems and methods
WO2020242896A3 (en) Treatment of angiopoietin like 7 (angptl7) related diseases
EP4397375A3 (en) Isoxazoline parasiticide formulations and methods for treating blepharitis
ZA202212328B (en) Oxymetazoline compositions and methods for treating ocular disorders
TW200621236A (en) Use of inhibitors of jun n-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
MX2022001069A (es) Composiciones y metodos para el tratamiento de la presbicia.
WO2021220061A3 (en) Heterodimer compositions and methods for the treatment of ocular disorders
JP6653898B1 (ja) 非侵襲的角膜又は強膜強化装置
CL2024003281A1 (es) Anticuerpos específicos contra la proteína 7 relacionada con la angiopoyetina y usos de estos
WO2023192828A3 (en) Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases
WO2023212707A3 (en) Therapeutic modulation of genes in myeloid lineage cells and uses thereof in ophthalmology
EP4559529A3 (en) Isocyclosporin a for topical treatment of ocular diseases
WO2023192691A3 (en) Methods and formulations for intranasal delivery of insulin in the treatment of diabetic eye disease
WO2024211322A3 (en) Ripasudil based ophthalmic treatments
CR20230190A (es) Compuesto degradante en un medicamento
MX2023001950A (es) Compuestos y formulaciones para el tratamiento de enfermedades oftalmicas.
WO2023283554A3 (en) Compositsons and methods for decreasing pigmentation
Štěpánková et al. Simultaneous bilateral acute angle-closure glaucoma in miller fisher syndrome
WO2007025275A3 (en) Control of induced elevated intraocular pressure